The Natural History of Disease: Why So Much Happens Before You Notice

A disease can begin before symptoms, but there is no universal hidden stage. This lesson separates susceptibility, biological change, detectability, symptoms, diagnosis and outcomes while explaining the benefits and limitations of screening.

Natural history is a model, not a promise The natural history of disease is the course a condition tends to follow without intervention. Prevention and treatment can redirect the course seen in practice. Natural history evidence usually describes patterns across groups. It cannot predict the exact timing, manifestations or outcome for one person. Not every disease develops slowly. Some begin suddenly, while others remain silent, regress, recur or never become clinically apparent. Possible landmarks along the course Several landmarks can help organise the timeline. They are not compulsory stages or a fixed sequence. Susceptibility means that personal or environmental factors increase probability before the relevant disease process has begun. Susceptibility is not disease. Biological onset is the point when the pathological process begins. This moment is often uncertain and may not be identifiable later. Subclinical disease means that a disease process exists without recognised symptoms. It may be detectable, remain undetectable, regress or never become clinically apparent. A detectable preclinical phase is the interval when a suitable test can identify the process before symptoms would usually lead to diagnosis. Clinically apparent disease produces symptoms or signs that bring the condition to attention. Diagnosis can still occur before, during or after this point. Possible outcomes include resolution, remission, persistence, progression, disability, complications or death. Treatment and protective factors can alter these outcomes. Risk, precursor change and disease are different A screening programme does not always search for established disease. It may identify increased chance, a precursor state or early disease. A precursor state is an abnormality that can sometimes develop into disease. It may also remain stable or regress. Finding a precursor does not mean that progression is inevitable. Its significance depends on the condition, degree of abnormality and evidence from follow up. This distinction matters because a positive result can represent increased probability rather than a diagnosis. Screening is not diagnosis Screening is offered to people without recognised symptoms to identify those with an increased chance of a condition or future problem. A screening test usually separates people who need further assessment from those who do not need it at that time. A diagnostic test investigates a symptom, abnormal finding or positive screening result. Diagnostic assessment may include several tests rather than one definitive procedure. People with symptoms should seek clinical assessment. They should not wait for a screening invitation or rely on a recent screening result. Earlier detection helps only under specific conditions A detectable preclinical phase is necessary for many screening programmes, but it is not enough by itself. The condition must be important, the test sufficiently accurate and the follow up pathway acceptable. Effective earlier action must improve outcomes. The UK National Screening Committee recommends programmes only when the complete pathway is expected to do more good than harm. This balance includes the screening test, further diagnostic procedures, treatment, practical burden and effects across the target population. Screening remains a personal choice. Balanced information should explain benefits, limitations and possible harms. No screening test is perfect A false positive result suggests increased chance when the target condition is not present. It can cause worry and lead to unnecessary procedures. A false negative result gives a lower chance result when the condition is present. It can create false reassurance and delay assessment. A negative result does not guarantee that the condition is absent. It also cannot prevent the condition developing later. A positive result does not usually establish the diagnosis. Further assessment determines whether disease, a precursor or another explanation is present. Earlier diagnosis does not always mean longer life Lead time bias occurs when earlier diagnosis makes survival after diagnosis appear longer without extending the person's lifetime. Imagine two identical disease courses ending on the same date. Screening may start the diagnosis clock earlier even when the outcome does not change. Screening programmes therefore need evidence about outcomes such as deaths, serious illness or quality of life. Survival time after diagnosis alone can mislead. Screening can also preferentially detect slower growing disease because it remains detectable for longer. Faster disease may develop between screening rounds. Overdiagnosis is a real diagnosis with no future harm Overdiagnosis means detecting a genuine condition that would never have caused symptoms or harm during that person's lifetime. It is different from a false positive result. The abnormality is real, but finding it does not improve health. Overdiagnosis can lead to overtreatment, complications, anxiety and long term medical follow up. Its frequency differs between conditions and programmes. This does not mean screening is generally harmful. It explains why the benefit and harm of each programme must be assessed separately. A bowel screening example NHS bowel cancer screening uses a faecal immunochemical test, called FIT, to look for small amounts of blood in stool. Blood can come from bowel cancer, polyps or less serious causes. A result saying further tests are needed does not diagnose cancer. The person is offered assessment with a specialist screening practitioner. Colonoscopy is usually considered to examine the bowel and remove or sample abnormalities when appropriate. Some polyps can develop into cancer over time, but not every polyp progresses. Removing suitable polyps can reduce future bowel cancer risk. A result saying no further tests are needed does not completely exclude bowel cancer. New symptoms still require assessment. Taking part in screening decisions Ask what the programme aims to prevent or improve. Ask what a positive, negative or uncertain result would mean. Ask about further tests, possible treatment, false results and overdiagnosis. You can also ask what evidence shows that the complete pathway improves health. Contact a GP for blood in stool, a persistent change in bowel habit, unexplained weight loss or continuing abdominal pain. Ask for urgent GP help or contact NHS 111 for black or dark red stool or bloody diarrhoea. Call 999 or go to A&E for non stop rectal bleeding, a large amount of blood, large clots or collapse. This lesson explains disease timelines and screening principles. It cannot show that you have an undetected condition or decide whether screening is suitable for you.

Disease timelines can include susceptibility, silent biological change, detectability, symptoms and several outcomes, but no sequence is universal. Screening is justified only when earlier identification and action improve health more than they cause harm.